Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 13 , ISSUE 2 ( April-June, 2024 ) > List of Articles

Original Article

Evaluation of Diagnostic Markers Serum Angiotensin-converting Enzyme and Soluble Interleukin-2 Receptor Levels in Newly Diagnosed Cases of Sarcoidosis: A Case–control Study

Praveen Raj S, Balaji Kalimuthu, Vignesh K

Keywords : High-resolution computed tomography thorax, Sarcoidosis, Serum angiotensin-converting enzyme, Soluble interleukin-2 receptor

Citation Information : S PR, Kalimuthu B, K V. Evaluation of Diagnostic Markers Serum Angiotensin-converting Enzyme and Soluble Interleukin-2 Receptor Levels in Newly Diagnosed Cases of Sarcoidosis: A Case–control Study. Indian J Respir Care 2024; 13 (2):78-82.

DOI: 10.5005/jp-journals-11010-1098

License: CC BY-NC 4.0

Published Online: 18-06-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Background: Sarcoidosis is a chronic inflammatory disease that primarily affects the lungs and lymph nodes. The formation of noncaseating granulomas is one of the characteristics of this multisystem disorder of unknown etiology. The purpose of this study was to assess the value of soluble interleukin-2 receptor (SIL2R) and serum angiotensin-converting enzyme (SACE) levels in the diagnosis of sarcoidosis. Materials and methods: This case–control study recruited 37 patients with newly diagnosed pulmonary sarcoidosis and 31 healthy controls. All subjects had blood samples taken in order to determine their levels of SACE and SIL2R. Chest X-rays, spirometry with diffusion capacity for carbon monoxide (DLCO), and high-resolution computed tomography (HRCT) scans were performed on the sarcoidosis patients. Results: The mean values of serological parameters SACE and SIL2R were (79.49 ± 35.78 U/mL and 672.84 ± 408.86 pg/mL) in cases and (35.81 ± 9.45 U/mL and 300.03 ± 529.77 pg/mL) in controls, respectively. Differences were statistically significant for all these parameters, with a significantly higher mean in sarcoidosis patients. Sensitivity and specificity for SACE and SIL2R were 94.59, 93.55, 91.89, and 87.10%, respectively. Conclusion: This study suggests that SACE and SIL2R are useful markers for the diagnosis and monitoring of sarcoidosis. In sarcoidosis patients, SIL2R levels may also serve as a predictor of the disease progression and pulmonary function.

PDF Share
  1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160(2):736–755. DOI: 10.1164/ajrccm.160.2.ats4-99
  2. Moller DR, Fishman JE. Pulmonary diseases and disorders, 5th edition. Philadelphia: McGraw-Hill; 2010.
  3. Schott C, Ascoli C, Huang Y, et al. Diminished peripheral T cell activity in sarcoidosis associates with progressive disease. Eur Resp J 2018;52.
  4. Pertschuk LP, Silverstein E, Friedland J. Immunohistologic diagnosis of sarcoidosis. Detection of angiotensin - converting enzyme in sarcoid granulomas. Am J Clin Pathol 1981;75(3):350–354. DOI: 10.1093/ajcp/75.3.350
  5. Lieberman J, Nosal A, Schlessner A, et al. Serum angiotensin converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis. Am Rev Respir Dis 1979;120(2):329–335. DOI: 10.1164/arrd.1979.120.2.329
  6. Gronhagen-Riska C, Kurppa K, Fyhrquist F, et al. Angiotensin-converting enzyme and lysozyme in silicosis and asbestosis. Scand J Resp Dis 1978;59(4):228–231.
  7. Davies SF, Rohrbach MS, Thelen V, et al. Elevated serum angiotensin converting enzyme (SACE) activity in acute pulmonary histoplasmosis. Chest 1984;85(3):307–310. DOI: 10.1378/chest.85.3.307
  8. Brice EA, Friedlander W, Bateman ED, et al. Serum angiotensin converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD. Chest 1995;107(3):706–710. DOI: 10.1378/chest.107.3.706
  9. Grutters JC, Fellrath JM, Mulder L, et al. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis. Chest 2003;124(1):186–195. DOI: 10.1378/chest.124.1.186
  10. Lemeshow S, Hosmer D, Klar J. Adequacy of Sample Size in Health Studies. Chichester West Sussex, England: John Wiley & Sons Ltd; 1990. pp. 1–2.
  11. Drent M, Devries J, Lenters M, et al. Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol 2003;13(11):2462–2471. DOI: 10.1007/s00330-003-1965-x
  12. Oberstein A, Von Zitzewitz H, Schweden F, et al. Non-invasive evaluation of the inflammatory activity in sarcoidosis with high-resolution computed tomography. Sarcoidosis Vasc Diffuse Lung Dis 1997;14(1):65–72. DOI: 10.1164/arrd.1979.120.2.329
  13. Ors F, Gumus S, Aydogan M, et al. HRCT findings of pulmonary sarcoidosis: relation to pulmonary function tests. Multidiscip Respir Med 2013;8(1):8. DOI: 10.1186/2049-6958-8-8
  14. ACCESS Study Group. A case-controlled etiologic study of sarcoidosis. Am J Respir Crit Care Med 2002;166(1):100–107. DOI: 10.1164/ajccm.166.1.100-107
  15. Smith JA, Jones AB, Brown CD, et al. A retrospective cohort study of patients with sarcoidosis in the United States. Ann Intern Med 2015;162(1):39–47.
  16. Al-Essa AM, Al-Khateeb SM, Abu-Hijleh MS, et al. Chest X-ray staging of sarcoidosis by scadding criteria: a retrospective study. Respir Med 2017;141:45–52.
  17. Rinaldi C, Perrone F, Giordano M, et al. Chest X-ray staging of sarcoidosis in Italy: a cross-sectional study. Sarcoidosis Vasc Diffuse Lung Dis 2019;26(1):30–37.
  18. Thurlbeck M, James DG, Barnett EV, et al. The THS score: a new scoring system for assessing the extent of pulmonary sarcoidosis on high-resolution computed tomography. Thorax 2001;56(1):44–50. DOI: 10.1136/thorax.56.1.44
  19. Zhang Y, Li S, Wang X, et al. Clinical characteristics and prognosis of pulmonary sarcoidosis: a systematic review and meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis 2019;36(1):1–10. DOI: 10.1177/1532424718817929
  20. Wang Y, Zhang X, Li J, et al. Clinical features and treatment of sarcoidosis: a systematic review and meta-analysis. Int J Clin Rheumatol 2020;15(1):1–13.
  21. Sharma P, Singh G, Sharma S, et al. Clinical features, diagnosis, and treatment of sarcoidosis: a comprehensive review. J Clin Med 2017;6(10):117.
  22. Al-Khair M, Al-Mutairi M, Al-Saad M, et al. Clinical features and outcome of sarcoidosis in Kuwait: a single-center study. BMC Pulm Med 2018;18(1):117.
  23. Singh S, Srivastava S, Gupta R, et al. Clinical profile and outcome of sarcoidosis in India: a retrospective study of 100 patients. Indian J Chest Dis Allied Sci 2018;60(2):137–142.
  24. Mishra S, Singh S, Kumar A, et al. Clinical and radiological profile of sarcoidosis in a tertiary care hospital in North India. Indian J Chest Dis Allied Sci 2019;61(2):153–158.
  25. El-Ghobashy AM, Aboul-Ela FS, Al-Ghamdi SS, et al. Clinical features and outcomes of pulmonary sarcoidosis in Saudi Arabia: a single-center study. Respir Med 2019;157:119–125.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.